Overview

Study of V117957 in Overactive Bladder Syndrome

Status:
Active, not recruiting

Trial end date:
2024-12-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to evaluate the safety, tolerability and efficacy of V117957 in subjects with overactive bladder syndrome, compared to placebo.

Phase:

Phase 1

Details

Lead Sponsor:

Imbrium Therapeutics

Collaborator:

Purdue Pharma LP